Cost-Benefit of Stockpiling Drugs for Influenza Pandemic
Open Access
- 1 August 2005
- journal article
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 11 (8) , 1280-1282
- https://doi.org/10.3201/eid1108.041156
Abstract
We analyzed strategies for the use of stockpiled antiviral drugs in the context of a future influenza pandemic and estimated cost-benefit ratios. Current stockpiling of oseltamivir appears to be cost-saving to the economy under several treatment strategies, including therapeutic treatment of patients and postexposure prophylactic treatment of patients' close contacts.Keywords
This publication has 21 references indexed in Scilit:
- Cooping Up Avian FulScientific American, 2005
- UK stocks up on antiviral drug to tackle flu outbreakBMJ, 2005
- Tackling the next influenza pandemicBMJ, 2004
- The Public’s Response to Severe Acute Respiratory Syndrome in Toronto and the United StatesClinical Infectious Diseases, 2004
- Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trialsBMJ, 2003
- Detection of Amantadine-Resistant Influenza A Virus Strains in Nursing Homes by PCR-Restriction Fragment Length Polymorphism Analysis with Nasopharyngeal SwabsJournal of Clinical Microbiology, 2002
- OseltamivirDrugs, 2001
- Use of the Selective Oral Neuraminidase Inhibitor Oseltamivir to Prevent InfluenzaNew England Journal of Medicine, 1999
- Emergence and Apparent Transmission of Rimantadine-Resistant Influenza A Virus in FamiliesNew England Journal of Medicine, 1989
- Elementary Methods of Cohort Analysis*International Journal of Epidemiology, 1984